Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2606

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2606
---
 may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our
product candidates are approved for a second or third line of therapy, the number of patients that may be eligible for treatment with
our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine
how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of
approved therapies for each such tumor type.

We
currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to
invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into
agreements with third parties to market and sell our products, we may not be able to generate product revenue.

We
have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates
ultimately receive regulatory approval, we expect to establish either an internal or external marketing and sales organization with technical
expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and,
to the extent we establish such organization in house, time consuming. We have no prior experience as a company in the marketing, sale
and distribution of pharmaceutical products and there are significant risks involved in establishing or managing a sales organization,
including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training
to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in
the development of our internal or external sales, marketing and distribution capabilities would adversely impact the commercialization
of these products. If we choose to collaborate with third parties that have direct sales forces and established distribution systems,
either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we may not
be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution
functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if
we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We
likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to
sell and market our products